Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells

Abstract

OBJECTIVE: To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab, Trastuzumab, Taxol and Insulin-like growth factor 1 receptor (IGF-1R)antibodies treatment in different estrogen. METHODS: RT-PCR was used to detect the expression of VEGF in SKBR-3 breast cancer cells under different concentrations of estrogen and VEGF monoclonal antibody, HER-2 monoclonal antibody, paclitaxel and IGF-1R antibody. At the same time, ELISA was used to detect the concentration of VEGF protein in the culture supernatant. RESULTS: The expression of VEGF in no estrogen group was 1.0618±0.0085 (VEGF/GAPDH); the expression of VEGF in low concentration group (50pg/L) was 1.0047±0.0061, the difference was statistically significant compared with the no estrogen group (P=0.002); the expression of VEGF in high concentration group (0.2 μg/mL) was 1.0868±0.0135, the difference was statistically significant compared with the no estrogen group (P<0.001). The expression of VEGF were 1.0496±0.0288 and 1.0618±0.0085 in Taxol group and contral Group (F=0.058), the expression of VEGF were 1.0884±0.0036, 1.0618 ±0.0085 in antibody of IGF-1R group and contral group (F=0.073), the expression of VEGF were 0.9887±0.0037, 1.0618±0.0085 in Trastuzumab group and contral group (F=0.075). The expression of VEGF in the paclitaxel group and the control group were 1.0496±0.0288 and 1.0618±0.0085(F=0.058);The expression of VEGF in IGF-1R group and control group were 1.0884±0.0036 and 1.0618±0.0085(F=0.073);The expression of VEGF in the trastuzumab group and the control group were 0.9887±0.0037 and 1.0618±0.0085(F=0.075); There was no significant change in the expression of VEGF in the paclitaxel group, the IGF-1R group antibody and the trastuzumab group with estrogen. The expression of VEGF in the bevacizumab group and the control group were 1.0057±0.0043 and 1.0618±0.0085( F=0.132, P=0.04), and There is no synergistic effect of estrogen and VEGF monoclonal antibody on the expression of VEGF. Conclusion: The influence of different estrogen on VEGF-expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells, and this has no synergistic effect with estrogen.. Bevacizumab increases the expression of VEGF, and this also has no synergistic effect with estrogen.